Suchen
Grifols SA
GRFSZur Watchlist hinzufügen
7.310USD
-0.090-1.22%
Handelsschluss 09-18 16:00（ET）
1.88BMarktkapitalisierung
9.40KGV TTM
mehr Informationen über Grifols SA Unternehmen
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
Grifols SA Profil
BörsenkürzelGRFS
Name des UnternehmensGrifols SA
IPO-datumMay 17, 2006
CEOAbia (Jose Ignacio)
Anzahl der mitarbeiter23833
WertpapierartDepository Receipt
GeschäftsjahresendeMay 17
AddresseParque Empresarial Can Sant Joan
StadtSANT CUGAT DEL VALLES
BörseNASDAQ OMX - NASDAQ BASIC
LandSpain
Postleitzahl08174
Telefon34935710000
Websitehttps://www.grifols.com/
BörsenkürzelGRFS
IPO-datumMay 17, 2006
CEOAbia (Jose Ignacio)
Führungskräfte von Grifols SA
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Enrique De La Torre
Mr. Enrique De La Torre
Chief Compliance Officer
Chief Compliance Officer
--
--
Mr. Roland Wandeler, Ph.D.
Mr. Roland Wandeler, Ph.D.
President - Biopharma
President - Biopharma
--
--
Ms. Irene Roche Font
Ms. Irene Roche Font
Vice President - Accounting and Financial Services
Vice President - Accounting and Financial Services
--
--
Ms. Montseratt Ribas Loveras
Ms. Montseratt Ribas Loveras
Chief Communication and Reputation Officer
Chief Communication and Reputation Officer
--
--
Dr. Ester Masllorens Llinas
Dr. Ester Masllorens Llinas
Independent Director
Independent Director
--
--
Ms. Joanna Susan Le Couilliard
Ms. Joanna Susan Le Couilliard
Independent Director
Independent Director
--
--
Mr. Tomas Daga Gelabert
Mr. Tomas Daga Gelabert
Other External Director
Other External Director
--
--
Mr. Raimon Grifols Roura
Mr. Raimon Grifols Roura
Vice Chairman of the Board, Proprietary Director
Vice Chairman of the Board, Proprietary Director
--
--
Ms. Nuria Martin Barnes
Ms. Nuria Martin Barnes
Non-Member Assistant Secretary of the Board of Directors
Non-Member Assistant Secretary of the Board of Directors
--
--
Mr. Ignacio Ramal Subira
Mr. Ignacio Ramal Subira
Chief Internal Audit & Enterprise Risk Management
Chief Internal Audit & Enterprise Risk Management
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Enrique De La Torre
Mr. Enrique De La Torre
Chief Compliance Officer
Chief Compliance Officer
--
--
Mr. Roland Wandeler, Ph.D.
Mr. Roland Wandeler, Ph.D.
President - Biopharma
President - Biopharma
--
--
Ms. Irene Roche Font
Ms. Irene Roche Font
Vice President - Accounting and Financial Services
Vice President - Accounting and Financial Services
--
--
Ms. Montseratt Ribas Loveras
Ms. Montseratt Ribas Loveras
Chief Communication and Reputation Officer
Chief Communication and Reputation Officer
--
--
Dr. Ester Masllorens Llinas
Dr. Ester Masllorens Llinas
Independent Director
Independent Director
--
--
Ms. Joanna Susan Le Couilliard
Ms. Joanna Susan Le Couilliard
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Grifols SA?
Die fünf größten Anteilseigner von Grifols SA sind: Mr. Enrique De La Torre
Wie viele Institutionen halten Anteile an Grifols SA (GRFS)?
Mit Stand vom 2026Q1 halten 346 Institutionen Anteile an Grifols SA, mit einem Gesamtmarktwert von etwa 148.94M, was 57.68% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -8688154.00 gestiegen.